Newsroom

Mar 18, 2019

NapaJen Pharma, Inc.:
INCJ Portfolio company, NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides

On March 18, 2019, INCJ portfolio company, NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary oligonucleotide delivery technology to develop novel agents, announced that the company has entered into a research collaboration with Astellas Pharma Inc. for the discovery and development of novel oligonucleotide therapeutics.

Press Relase

NapaJen Pharma, Inc.

Investment Structure

Related Press Releases

Dec 25, 2018
INCJ to make follow-on investment in NapaJen Pharma, Inc. Bio-venture aims to develop systemic nucleic-acid drugs originating in Japan
Dec 07, 2016
INCJ to make additional investment in NapaJen Pharma, Inc.
Feb 03, 2014
INCJ to invest in NapaJen Pharma: A Bio-venture aims to develop nucleic-acid drugs using delivary technology platform

Investment Information

HOME
About Us
Our Business
Newsroom
Our Investments